125 related articles for article (PubMed ID: 12769667)
41. The mutational signature of alpha-hydroxytamoxifen at Hprt locus in Chinese hamster cells.
Yadollahi-Farsani M; Davies DS; Boobis AR
Carcinogenesis; 2002 Nov; 23(11):1947-52. PubMed ID: 12419845
[TBL] [Abstract][Full Text] [Related]
42. Induction of lacI mutations in Big Blue rats treated with tamoxifen and alpha-hydroxytamoxifen.
Gamboa da Costa G; Manjanatha MG; Marques MM; Beland FA
Cancer Lett; 2002 Feb; 176(1):37-45. PubMed ID: 11790452
[TBL] [Abstract][Full Text] [Related]
43. N-demethylation accompanies alpha-hydroxylation in the metabolic activation of tamoxifen in rat liver cells.
Phillips DH; Hewer A; Horton MN; Cole KJ; Carmichael PL; Davis W; Osborne MR
Carcinogenesis; 1999 Oct; 20(10):2003-9. PubMed ID: 10506117
[TBL] [Abstract][Full Text] [Related]
44. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.
Zhao XJ; Jones DR; Wang YH; Grimm SW; Hall SD
Xenobiotica; 2002 Oct; 32(10):863-78. PubMed ID: 12419016
[TBL] [Abstract][Full Text] [Related]
45. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
[TBL] [Abstract][Full Text] [Related]
46. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study.
Pukkala E; Kyyrönen P; Sankila R; Holli K
Int J Cancer; 2002 Jul; 100(3):337-41. PubMed ID: 12115550
[TBL] [Abstract][Full Text] [Related]
47. The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation.
Davis W; Venitt S; Phillips DH
Carcinogenesis; 1998 May; 19(5):861-6. PubMed ID: 9635875
[TBL] [Abstract][Full Text] [Related]
48. Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen.
Gamboa da Costa G; Marques MM; Fu X; Churchwell MI; Wang YP; Doerge DR; Beland FA
Cancer Lett; 2007 Nov; 257(2):191-8. PubMed ID: 17765393
[TBL] [Abstract][Full Text] [Related]
49. Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo.
Moorthy B; Sriram P; Randerath E; Randerath K
Biochem Pharmacol; 1997 Mar; 53(5):663-9. PubMed ID: 9113085
[TBL] [Abstract][Full Text] [Related]
50. Tamoxifen in postmenopausal women a safety perspective.
Robinson E; Kimmick GG; Muss HB
Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
[TBL] [Abstract][Full Text] [Related]
51. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
[TBL] [Abstract][Full Text] [Related]
53. Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots.
Liapis E; McLuckie KI; Lewis PD; Farmer PB; Brown K
Nucleic Acids Res; 2008 Oct; 36(18):5933-45. PubMed ID: 18805907
[TBL] [Abstract][Full Text] [Related]
54. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo.
Beland FA; McDaniel LP; Marques MM
Carcinogenesis; 1999 Mar; 20(3):471-7. PubMed ID: 10190564
[TBL] [Abstract][Full Text] [Related]
56. 4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells.
Osborne MR; Davis W; Hewer AJ; Hardcastle IR; Phillips DH
Chem Res Toxicol; 1999 Feb; 12(2):151-8. PubMed ID: 10027792
[TBL] [Abstract][Full Text] [Related]
57. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract][Full Text] [Related]
58. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study.
Parkkari M; Paakkala AM; Salminen L; Holli K;
Acta Ophthalmol Scand; 2003 Oct; 81(5):495-9. PubMed ID: 14510798
[TBL] [Abstract][Full Text] [Related]
59. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
